The potential of thismodified glycopeptide as a mimic of a tumor-associated MUC1 antigentriggered us to test it in vivo, which proved that antibodies generatedin mice with this synthetic antigen recognized human cancer cell lineswith high selectivity. This evidence concerns the gene MUC1 and neoplasm.